33821-61-3

Upstream product

• 675-10-5 4-hydroxy-6-methyl-2-pyron 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 70254-61-4 4-hydroxy-6-methyl-2H-pyran-2-one 
• 541-98-0 6-methyl-pyran-2,4-dione 

Downstream Products

• 1571135-28-8 1-[1-(4-cyanophenyl)ethyl]-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 450841-11-9 1-(3-chlorophenyl)-6-methyl-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid 
• 33821-59-9 1,6-dimethyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 33821-58-8 6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 1571132-69-8 C₂₂H₁₆F₃N₃O₂ 
• 1570079-68-3 1-(4-cyano-benzyl)-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid 
• 1571133-23-7 1-(4-cyanobenzyl)-6-methyl-4-oxo-5-phenyl-1,4-dihydropyridine-3-carboxylic acid 4-(methanesulfonyl)benzylamide 
• 1571132-15-4 1-(4-cyanobenzyl)-6-methyl-4-oxo-5-(3-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylic acid (2-hydroxyethyl)amide 
• 1571135-06-2 1-(4-cyanobenzyl)-6-methyl-4-oxo-5-(3-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylic acid cyanomethylamide 
• 1571135-33-5 5-bromo-1-(4-cyanobenzyl)-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-methanesulfonylbenzylamide 
• 1571132-31-4 1-(4-cyanobenzyl)-6-methyl-4-oxo-5-(3-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylic acid (2,3-dihydroxypropyl)amide 
• 1570079-33-2 1-(4-cyano-benzyl)-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 
• 1570080-14-6 5-bromo-1-(4-cyano-benzyl)-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid 
• 1570075-93-2 5-(3-(difluoromethyl)phenyl)-1-isopropyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 4-(N-cyano-S-(methyl)sulfonimidoyl)benzylamide 

Relevant academic research and scientific papers

Relationship between solid state structure and solution stability of copper(ii)-hydroxypyridinecarboxylate complexes

The complementary solid state/solution studies of the systematic series of bioactive ligands 3-hydroxy-1-methyl-4-pyridinecarboxylate (L1), 3-hydroxy-1,2,6-trimethyl-4-pyridinecarboxylate (L2), 4-hydroxy-1-methyl-3-pyridinecarboxylate (L3), 4-hydroxy-1,6-

COMPOUNDS AND METHODS OF USE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

Provided herein are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, R1, R2, R3, R4, R5, R6 and R7 are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS

This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmona

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

P01-2864-ff 32/132 -132- ABSTRACT This invention relates to substituted 4-pyridones of formula R 1a R 7 R 6 R R 3 N O O N H R 4 R 2 R 1b A 1 and their use as inhibitors ofneutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.